Safety Reporting of Erwinia L asparaginase-Pediatric
Back to Oncology/Cancer Clinical Trials Main PageCPMC Cancer Services
| Principal Investigator/Contact Information | Protocol Title | Patient Population | Recruitment Period |
| Principal Investigator: CPMC Oncologists Contact: Catherine Carr 415-600-1369 | Protocol for the use and safety reporting of Erwinia L asparaginase under conditions of a shortage of E.coli derived asparaginase in the USA. Erwinia | None-Safety Reporting Protocol | Open |
updated: 4/22/09
Back to top